Denosumab

證據等級: L5

預測適應症: 2 個

Denosumab: From Unspecified Original Indication to Severe Nonproliferative Diabetic Retinopathy

One-Sentence Summary

Denosumab is a RANKL-targeted monoclonal antibody; this evidence pack does not contain data on its original approved indication or mechanism of action (data gaps DG001/DG002). The TxGNN model predicts potential efficacy for Severe Nonproliferative Diabetic Retinopathy, but currently no clinical trials and no literature support this specific direction.

Quick Overview

Item	Content
Original Indication	Not specified in evidence pack (original MOA and indication data are both flagged as data gaps — see DG001/DG002)
Predicted New Indication	Severe Nonproliferative Diabetic Retinopathy
TxGNN Prediction Score	99.63%
Evidence Level	L5 (model prediction only, no supporting studies)
Market Status (Taiwan)	未上市 (Not Marketed)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for denosumab in this evidence pack (DG002, High severity). Without confirmed original indication or MOA data, no direct mechanistic bridge can be established to severe nonproliferative diabetic retinopathy (NPDR).

The repurposing rationale notes that the OPG/RANKL/RANK signaling axis has been theoretically associated with vascular endothelial dysfunction and pathological angiogenesis, which are relevant to diabetic microvascular disease. However, this link is speculative — it is not derived from any training data, clinical trial, or publication specific to severe NPDR. The 0.996 TxGNN score reflects graph-neural-network connection strength only, not clinical or mechanistic validation.

Given the missing MOA and original indication data, this prediction should be treated as a pure hypothesis-generation signal rather than a mechanistically substantiated candidate.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No authorizations on record (0 licenses; not marketed)

Safety Considerations

Please refer to the package insert for safety information.

(Key warnings, contraindications, and drug interaction data are all currently unavailable — DG001, Blocking severity, must be resolved via TFDA label retrieval before any safety assessment can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests solely on a TxGNN connectivity score (L5) with zero supporting clinical trials or literature, and two unresolved data gaps — missing TFDA label/safety data (Blocking) and missing MOA (High) — prevent even a preliminary S1 safety evaluation.

To proceed, the following is needed:

TFDA package insert (warnings, contraindications) — DG001, blocking
Denosumab mechanism of action data from DrugBank — DG002
Original approved indication(s) to establish original-to-new indication rationale
Disease-specific (severe NPDR) clinical or preclinical evidence; note that the broader "diabetic retinopathy" category (rank 2, score 0.992) already has L4 evidence (1 Phase 3 trial, 2 publications) and may be a more tractable starting point for further investigation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.